Nepafenac
| Evidence Level: L2 | Predicted Indications: 10 |
Table of Contents
Nepafenac: From Postoperative Ocular Inflammation to Eye Disease
One-Sentence Summary
Nepafenac is a topical NSAID eye drop (a prodrug of amfenac), marketed in Canada as NEVANAC and ILEVRO for eye conditions. The TxGNN model predicts it may be effective for eye disease (a broad label), with 40 clinical trials and 20 publications currently supporting this direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not specified in the Canadian licence records (marketed ophthalmic NSAID, used for inflammation and pain after cataract surgery) |
| Predicted New Indication | Eye disease |
| TxGNN Prediction Score | 0.9985 |
| Evidence Level | L2 |
| Canada Market Status | Marketed (marketed DINs: 2 of 2) |
| Number of DINs | 2 (marketed: 2) |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data was not available in the compiled data. Based on the literature, nepafenac is a prodrug that ocular tissue enzymes convert to amfenac, a COX-1/COX-2 inhibitor. By reducing prostaglandin synthesis, it lowers intraocular inflammation, pain, and breakdown of the blood-retinal barrier.
“Eye disease” is a very broad label and is already largely covered by existing ophthalmic use, namely inflammation and pain after cataract surgery. The strongest evidence is for post-cataract-surgery use and for preventing macular edema, including in diabetic patients. The prediction is not specific to any single disease entity.
Other predicted indications were also reviewed. Their support is much weaker:
- Vitreous detachment (L4): one biomarker study in retinal detachment, which is a related but different condition.
- Optic papillitis (L4): only a rabbit retinal-edema study, with no clinical data.
- Seven further predictions (L5): hypotrichosis simplex of the scalp, seborrheic keratosis, von Hippel anomaly, congenital hypotrichosis milia, McPherson-Robertson-Cammarano syndrome, lagophthalmos, and vulvar inverted follicular keratosis. These have no trials, literature, or plausible mechanism and are prediction only.
Clinical Trial Evidence
The table lists the 10 most relevant of the 40 trials identified, prioritising completed Phase 3 and large Phase 2 studies.
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT01109173 | Phase 3 | Completed | 2120 | Nepafenac 0.3% for prevention and treatment of inflammation and pain after cataract surgery |
| NCT01853072 | Phase 3 | Completed | 881 | Nepafenac 0.3% once daily vs vehicle in diabetic patients after cataract surgery |
| NCT01872611 | Phase 3 | Completed | 819 | Same design as above (companion study) for clinical outcomes in diabetic patients |
| NCT03499873 | Phase 3 | Completed | 448 | Bioequivalence of generic nepafenac 0.3% vs ILEVRO for pain and inflammation after cataract surgery |
| NCT00333255 | Phase 3 | Completed | 267 | NEVANAC 0.1% vs Acular LS for inflammation around cataract surgery |
| NCT01426854 | Phase 3 | Completed | 260 | Nepafenac 0.1% vs placebo after cataract surgery in Chinese adults |
| NCT00405730 | Phase 3 | Completed | 227 | Nepafenac 0.1% vs ketorolac vs placebo for inflammation and pain after cataract surgery (European study) |
| NCT01318499 | Phase 2 | Completed | 1342 | Nepafenac 0.3% vs 0.1% vs vehicle for inflammation and pain after cataract surgery |
| NCT00782717 | Phase 2 | Completed | 263 | NEVANAC 0.1% vs vehicle for macular edema after cataract surgery in diabetic retinopathy |
| NCT03025945 | N/A | Completed | 662 | Adjunctive nepafenac 0.3% vs placebo for preventing pseudophakic cystoid macular edema |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 39095467 | 2024 | Systematic review / network meta-analysis | Eye (London) | Compared topical NSAIDs for macular thickening, visual outcome and intraocular pressure after phacoemulsification |
| 34120417 | 2021 | RCT | Korean J Ophthalmol | Nepafenac 0.1% vs prednisolone 1% for inflammation control after micro-incisional cataract surgery |
| 32672612 | 2020 | RCT | Ophthalmology Glaucoma | Nepafenac 0.1% vs prednisolone acetate 1% after laser peripheral iridotomy |
| 41039316 | 2025 | Comparative study | BMC Ophthalmology | Compared analgesic efficacy of 7 topical NSAIDs for pain during panretinal photocoagulation |
| 34210237 | 2022 | Review | Clin Exp Optom | Nepafenac in cataract surgery: high ocular penetration and low side-effect profile |
| 26502088 | 2016 | Review | Dev Ophthalmol | NSAIDs in retinal diseases, acting through prostaglandin inhibition |
| 25686158 | 2015 | Systematic review | Cochrane Database Syst Rev | Topical NSAIDs for diabetic cystoid macular oedema |
| 26474497 | 2016 | Preclinical PK study | Exp Eye Res | Topical nepafenac and amfenac reach the posterior segment of the eye |
| 17259381 | 2007 | Animal study | Diabetes | Topical nepafenac inhibited early diabetes-induced retinal microvascular disease in rats |
| 17964407 | 2007 | Case report | J Cataract Refract Surg | Corneal melt (perforation) with nepafenac in a patient with graft-versus-host disease |
Canada Market Information
| DIN | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 02308983 | NEVANAC | Not listed | Not listed |
| 02411393 | ILEVRO | Not listed | Not listed |
Safety Considerations
- Corneal risk: A published case report describes corneal melt with nepafenac after cataract surgery in a patient with a predisposing condition (graft-versus-host disease). Topical NSAIDs may promote corneal melting in compromised corneas.
- Conditions flagged in the knowledge graph: The TxGNN knowledge graph links nepafenac to contraindication-type relationships with rheumatoid arthritis, diabetes mellitus, diabetic ketoacidosis, blood coagulation disease, keratitis, keratoconjunctivitis, dry eye syndrome, xerophthalmia, and corneal ulcer. These come from a knowledge graph, not from label text, and need confirmation against the product monograph.
- Drug interactions: No interaction data were found.
Please refer to the package insert for the full warnings and contraindications.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: Multiple completed Phase 3 trials (several with more than 800 participants) support nepafenac for inflammation, pain and macular edema prevention around cataract surgery, and it is already marketed in Canada. However, “eye disease” is too broad to be a distinct new indication, and evidence for the other predicted diseases is weak or absent. Any expansion should be limited to specific, well-defined ocular conditions.
To proceed, the following is needed:
- Retrieve the Health Canada product monograph to confirm approved indications, warnings and contraindications (a blocking gap for safety screening)
- Obtain detailed mechanism-of-action data from DrugBank
- Define a specific target condition rather than the broad “eye disease” label
- Establish a corneal-safety monitoring plan, especially for patients with keratitis, dry eye, corneal ulcer or diabetes
- Keep the weakly supported predictions (optic papillitis, vitreous detachment and the dermatologic or rare-disease predictions) on Hold pending any clinical evidence
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.